Sartorius Stedim Biotech: Information on Document Availability
21 Febrero 2018 - 2:30AM
Business Wire
Regulatory News:
Sartorius Stedim Biotech Group’s Annual Report 2017 is now
available at
http://www.sartorius-france.fr/en/company/investor-relations/sartorius-stedim-biotech-sa/
It contains the following information:
- Business development for fiscal 2017 and the 2018 forecast for
the Sartorius Stedim Biotech Group
- Consolidated financial statements for the year ended December
31, 2017
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech (Paris:DIM) is a leading international
supplier of products and services that enable the biopharmaceutical
industry to develop and manufacture drugs safely and efficiently.
As a total solutions provider, Sartorius Stedim Biotech offers a
portfolio covering nearly all steps of biopharmaceutical
manufacture. The company focuses on single-use technologies and
value-added services to meet the rapidly changing technology
requirements of the industry it serves. Headquartered in Aubagne,
France, Sartorius Stedim Biotech is quoted on the Eurolist of
Euronext Paris. With its own manufacturing and R&D sites in
Europe, North America and Asia and an international network of
sales companies, Sartorius Stedim Biotech has a global reach. In
2017, the company employed approx. 5,100 people, and earned sales
revenue of €1,081.0 million.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180221005539/en/
Sartorius Stedim BiotechMirko KochManager Investor
RelationsPhone: +49(0)551.308.2402mirko.koch@sartorius.com
Sartorius Stedim Biotech (EU:DIM)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Sartorius Stedim Biotech (EU:DIM)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
Real-Time news about Sartorius Stedim Biotech SA (Euronext): 0 recent articles
Más de Sartorius Sted Bio Artículos de Noticias